Dynavax Technologies (DVAX) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Dynavax Technologies (DVAX) over the last 17 years, with Q3 2025 value amounting to $51.9 million.
- Dynavax Technologies' Accumulated Expenses fell 409.04% to $51.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.9 million, marking a year-over-year decrease of 409.04%. This contributed to the annual value of $61.1 million for FY2024, which is 2349.54% up from last year.
- Dynavax Technologies' Accumulated Expenses amounted to $51.9 million in Q3 2025, which was down 409.04% from $66.0 million recorded in Q2 2025.
- Dynavax Technologies' Accumulated Expenses' 5-year high stood at $87.9 million during Q3 2021, with a 5-year trough of $16.1 million in Q1 2021.
- Moreover, its 5-year median value for Accumulated Expenses was $45.8 million (2024), whereas its average is $43.9 million.
- In the last 5 years, Dynavax Technologies' Accumulated Expenses soared by 41134.25% in 2021 and then tumbled by 5653.62% in 2022.
- Quarter analysis of 5 years shows Dynavax Technologies' Accumulated Expenses stood at $49.8 million in 2021, then plummeted by 38.31% to $30.7 million in 2022, then surged by 60.97% to $49.4 million in 2023, then grew by 23.5% to $61.1 million in 2024, then dropped by 15.03% to $51.9 million in 2025.
- Its Accumulated Expenses stands at $51.9 million for Q3 2025, versus $66.0 million for Q2 2025 and $54.3 million for Q1 2025.